WO2020165715A1 - Nasal inhaler with combined treatments - Google Patents

Nasal inhaler with combined treatments Download PDF

Info

Publication number
WO2020165715A1
WO2020165715A1 PCT/IB2020/050998 IB2020050998W WO2020165715A1 WO 2020165715 A1 WO2020165715 A1 WO 2020165715A1 IB 2020050998 W IB2020050998 W IB 2020050998W WO 2020165715 A1 WO2020165715 A1 WO 2020165715A1
Authority
WO
WIPO (PCT)
Prior art keywords
cannabis
patient
therapy
afflictions
based therapy
Prior art date
Application number
PCT/IB2020/050998
Other languages
French (fr)
Inventor
Michael CABIGON
Steven Splinter
Denis TASCHUK
Original Assignee
Radient Technologies Innovations Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201962804073P priority Critical
Priority to US62/804,073 priority
Application filed by Radient Technologies Innovations Inc. filed Critical Radient Technologies Innovations Inc.
Publication of WO2020165715A1 publication Critical patent/WO2020165715A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/06Respiratory or anaesthetic masks
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/23Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G16H20/13ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0065Inhalators with dosage or measuring devices
    • A61M15/0068Indicating or counting the number of dispensed doses or of remaining doses
    • A61M15/0083Timers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/009Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0091Inhalators mechanically breath-triggered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/08Inhaling devices inserted into the nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/0057Pumps therefor
    • A61M16/0066Blowers or centrifugal pumps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/10Preparation of respiratory gases or vapours
    • A61M16/14Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/14Detection of the presence or absence of a tube, a connector or a container in an apparatus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/18General characteristics of the apparatus with alarm
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/33Controlling, regulating or measuring
    • A61M2205/3303Using a biosensor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/35Communication
    • A61M2205/3546Range
    • A61M2205/3553Range remote, e.g. between patient's home and doctor's office
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/35Communication
    • A61M2205/3576Communication with non implanted data transmission devices, e.g. using external transmitter or receiver
    • A61M2205/3592Communication with non implanted data transmission devices, e.g. using external transmitter or receiver using telemetric means, e.g. radio or optical transmission
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/50General characteristics of the apparatus with microprocessors or computers
    • A61M2205/502User interfaces, e.g. screens or keyboards
    • A61M2205/505Touch-screens; Virtual keyboard or keypads; Virtual buttons; Soft keys; Mouse touches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/50General characteristics of the apparatus with microprocessors or computers
    • A61M2205/52General characteristics of the apparatus with microprocessors or computers with memories providing a history of measured variating parameters of apparatus or patient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/58Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/581Means for facilitating use, e.g. by people with impaired vision by audible feedback
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/58Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/583Means for facilitating use, e.g. by people with impaired vision by visual feedback
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/60General characteristics of the apparatus with identification means
    • A61M2205/6009General characteristics of the apparatus with identification means for matching patient with his treatment, e.g. to improve transfusion security
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00Measuring parameters of the user
    • A61M2230/04Heartbeat characteristics, e.g. ECG, blood pressure modulation
    • A61M2230/06Heartbeat rate only
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00Measuring parameters of the user
    • A61M2230/20Blood composition characteristics
    • A61M2230/205Blood composition characteristics partial oxygen pressure (P-O2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00Measuring parameters of the user
    • A61M2230/30Blood pressure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00Measuring parameters of the user
    • A61M2230/40Respiratory characteristics
    • A61M2230/42Rate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00Measuring parameters of the user
    • A61M2230/50Temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/60Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78Ring systems having three or more relevant rings
    • C07D311/80Dibenzopyrans; Hydrogenated dibenzopyrans

Abstract

Methods and systems for generating a cannabis-based therapy including an inhalable cannabis derived compound are disclosed. The methods and systems include a patient portal and a server having a matching system stored there, on the matching system further including a matching algorithm for matching a plurality of patient parameters and afflictions with a distribution device operable to dispense an inhalable cannabis-based therapy to a patient. The inhalable cannabis-based therapy including a formulation having a cannabis derived compound and a set of therapy instructions including a dosage, a frequency, and a duration of the therapy.

Description

NASAL INHALER WITH COMBINED TREATMENTS
CROSS-REFERENCE TO RELATED APPLICATION
[0001] The present patent application claims the priority benefit of U.S. provisional patent application number 62/804,073 filed February 11, 2019, the disclosure of which is incorporated by reference herein.
BACKGROUND OF THE INVENTION
1. Field of the Disclosure
[0002] The present disclosure is generally related to systems and methods for dispensing an inhalable cannabis-derived compound to a patient. More specifically, the present disclosure is related to inhalable cannabis-derived compounds delivered through a distribution device to treat various afflictions.
2. Description of the Related Art
[0003] Cannabis is a genus belonging to the family cannabaceae. There are three common species of cannabis including Cannabis stavia. Cannabis indica, and Cannabis ruderalis. The genus cannabaceae is indigenous to Central Asia and the Indian subcontinent and has a long history being used for medicinal, therapeutic, and recreational purposes. Cannabis is known, for example, to be capable of relieving nausea (such as that accompanying chemotherapy), pain, vomiting, spasticity in multiple sclerosis, and increase hunger in anorexia. The importance of cannabis in therapeutics is emphasized by the ever-increasing number of research publications related to the new indications for cannabis. For example, pharmaceutical research companies are presently developing new, natural cannabinoid formulations and delivery systems to meet various regulatory requirements. [0004] Cannabis contains a unique class of terpeno-phenolic compounds known as cannabinoids, or phytocannabinoi ds, which have been extensively studied since the discovery of the chemical structure of the principle cannabinoid, detita-9-tetrahydrocannabinol (Delta-9- THC), commonly known as THC. Cannabidiol (CBD), is the major cannabinoid substituent in hemp cannabis. CBD is non-psychoactive and is widely known to have therapeutic potential for a variety of medical conditions including, but not limited to, those described above. Over 113 phytocannabinoids have been identified.
[0005] Historical delivery methods for cannabis have involved smoking, or combusting, the dried cannabis plant material. However, smoking can have adverse effects on the respiratory system via the production of potentially toxic substances. Alternative delivery methods, such as inhaling vaporized cannabinoid-containing liquids, often called "vape liquids", may provide a safer means for delivery of cannabinoids. However, vaporizing vape liquids still requires the application of heat to the cannabinoid material and there is some concern that if the heating temperature is not well controlled, the process may produce toxins from the various other components of the formulated vape liquids.
[0006] Currently, clinical trials have investigated whether cannabinoids, ether in natural or synthetic form (such as, dronabinol), may be indicated for reduction of symptoms in various afflictions including, but not limited to, sleep apnea, nasal congestion, sore throats, and the like. It is known in the art that many cannabinoids, such as CBD, can help improve sleep function in adults, and provide relief from sleep disorders and other minor ailments. A synergistic effect may exist between therapeutic cannabis treatments and inhalation devices, but currently, no such product or treatment exist
SUMMARY OF THE CLAIMED INVENTION
[0007] Examples of the present disclosure provide systems and methods for providing an inhalable cannabis-based therapy, including a formulation having one or more cannabis derivative compounds and one or more additives, to a user via a distribution device. In particular, a system for matching a cannabis-based therapy for one or more acute or chronic conditions to a user is described. The matching system can include a matching system that is operable to access a patient's database and determine the optimum distribution device and cannabis derived compound to treat a user's affliction. The matched cannabis-based therapy can then be transmitted from the matching system to a patient' s portal where the user can place and order for one or more of the distribution device and cannabis derived compound.
[0008] In addition to the matching a cannabis-based therapy to a user, the systems and methods described herein also provide a cannabis attachment which can be coupled with a distribution device. The cannabis attachment can be a vessel operable to contain a cannabis derived compound and can be sized to be inserted into a distribution device. The cannabis derived compound can then be disseminated from the distribution device to a patient in the form of an inhalable treatment.
BRIEF DESCRIPTIONS OF THE DRAWINGS
[0009] FIG. 1 illustrates an exemplary cannabis distribution device for use with inhalable cannabis-derived compounds in accordance with the present disclosure.
[0010] FIGS. 2A and 2B illustrate exemplary system which can be used to disperse a cannabis-based therapy in accordance with the present disclosure.
[0011] FIG. 3 is a flowchart illustrating an exemplary method for using a regulator software to dispense a cannabis derived compound in accordance with the present disclosure.
[0012] FIG. 4 is a flowchart illustrating an exemplary method for using a patient portal in accordance with the present disclosure.
[0013] FIG.5 is a flowchart illustrating a method for using the matching algorithm in accordance with the present disclosure.
[0014] FIG. 6 is a flowchart illustrating a method for using an ordering system in accordance with the present disclosure.
DETAILED DESCRIPTION
[0015] The present disclosure presents a system and method for the distribution of an inhalable cannabis-based therapy, the cannabis-based therapy including a formulation comprising one or more cannabis derived compounds and one or more additives. The cannabis- based therapy can be distributed through a therapeutic distribution device placed on the face of a user. Furthermore, the present disclosure describes a cannabis attachment which can contain the cannabis derived compound and can be coupled with the distribution device which can simultaneously deliver the benefits of a cannabis treatment and an inhalation device. In at least one example, the present disclosure relates to the inhalation of cannabinoid-containing aerosols via, for example in a metered dose inhaler, which may offer a preferred method of lung delivery as opposed to the inhalation of combusted cannabinoids. Such metered inhalers, however, can generally contain a relatively small reservoir and thus can result in the delivery of very concentrated doses. Further, in metered inhalers the entire dose of the formulation is typically delivered at once and so it is difficult for a patient dose to be titrated over longer periods of time, providing a more sustained bioavailability of the cannabinoids.
[0016] FIG. 1 illustrates an exemplary system 100 for providing an inhalable cannabis- derived compound to a user. The system 100 can include a user device 110, a server 120, and a cannabis distribution device 140. The user device 110 can be any portable user device induding, but not limited to, a personal computing device, a mobile phone, a tablet, a computer, or any other computing device. The user device 110 can allow users to access a patient portal 112, for example via an application. The patient portal 112 can allow users to enter patient parameters into a patient database 114 stored on the patient portal 112. The patient parameters entered into the patient database 114 can include, but are not limited to, patient age, weight, gender, and affliction. Patient afflictions can include, but are not limited to, acute or chronic conditions relating to ailments such as sleep related disorders (inducting, but not limited to, apnea, hypopnea, or continuous or sustained reduction in ventilation), anxiety, sore throat, nasal congestion, neuropathic pain, nausea, motion sickness, arthritis, neurodegenerative diseases or any other ailment that has been determined to be alleviated by the ingestion of cannabinoids.
[0017] The user device 110 can be communicable with a server 120 via a communication network 160 capable of providing a connection between the user device 110, server 120, biometric device 130, and distribution device 140. The communications network 160 as described herein may be wired and/or a wireless network. If the communications network 170 is wireless, the communication network 170 may be implemented using communication techniques such as Visible Light Communication (VLC), Worldwide Interoperability for Microwave Access (WiMAX), Long Term Evolution (LTE), Wireless Local Area Network (WLAN), Infrared (IR) communication, Public Switched Telephone Network (PSTN), Radio waves, and other communication techniques known in the art. The communication network 160 may allow ubiquitous access to shared pools of configurable system resources and higher-level services that can be rapidly provisioned with minimal management effort, often over Internet and relies on sharing of resources to achieve coherence and economies of scale, like a public utility, while third-party clouds 150 enable organizations to focus on their core businesses instead of expending resources on computer infrastructure and maintenance.
[0018] The server 120 can have a memory operable to store instructions thereon and can be operable to receive data via the communications network 160. The server 120 can further include a matching system 122 which is operable to match a patient with a cannabis distribution device 140 based on patient parameters and affliction. The cannabis distribution device 140 can be any device suitable to facilitate the ingestion of a cannabis derivative compound 142 through the nasal passages and lungs. The matching system 122 can include a device database 124 and a matching algorithm 126. The device database 124 is a database containing various therapeutic cannabis distribution devices, cannabis-derived compounds, and recommended dosages for specific patients and diseases. The matching algorithm 126 is an algorithm that is operable to match the patient parameters received from the patient portal 112 to a therapeutic cannabis distribution device of the device database 124. The Matched device can be transmitted from the server 120 to the user device 110. The patient portal 112 can also be used provide a user with a recommendation for a cannabis distribution device 140 corresponding to the user's affliction, as determined by the matching algorithm 126. The corresponding distribution device 140 and/or cannabis derived compounds 142 can be ordered via an ordering system 116 accessible through the patient portal 112.
[0019] The system 100 for providing an inhalable cannabis-derived compound to a user can further include a distribution device 140 as described above. The distribution device 140 can be a therapeutic cannabis distribution device including, but not limited to an inhalation device. In at least one example, the distribution device 140 can include, but is not limited to, a face mask, a surgical mask, a non-forced air device, a forced air device, a positive airway pressure ventilator, a continuous positive airway pressure (CPAP) mask, a positive end-expiratory pressure (PEEP) ventilator, an oral mask, a naso-oral mask, a metered inhaler, a manually actuated inhaler, a breath-actuated inhaler, a mist inhaler, a nasal inhaler, a nasal pressure device, a maxillary advancement device (MAD), or any other device suitable to form an aerosol having the cannabis derived compound therein. In at least one example, the distribution device 140 can be single use. In the alternative, the distribution device 140 can be multi-use. The distribution device 140 is described in greater detail with respect to FIGS. 2A and 2B. The distribution device 140 can include a cannabis derived compound 142 suitable for consumption by inhalation. The cannabis derived compound 142 can include any compound derived from a cannabis plant. Cannabis plants consist of over 500 unique chemical compounds, including over 100 cannabinoids, including, but not limited to, tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromene (CBC), and carmabigerol (CBG). Cannbis plants can also consist of over 200 terpenes, including myrcene, limonene, linalool, caryophyllene, alpha-pinene, beta-pinene, alpha-bisabolol, eucalyptol, trans- nerolido, humulene, delta 3 carene, camphene, bomeol, berpineol, valencene, geraniol, etc. The cannabis derived compound 142 can be any cannabinoid or pharmaceutically acceptable salt thereof. In at least one example, when the distribution device 140 is in use, the effects of the cannabis derived compound 142 on the user can be monitored by a biometric monitoring device 130. The biometric monitoring device 130 can be any device suitable to quantify data collected from one or more biosensors which can measure a biological response. In at least one example, the biometric monitoring device 130 can be internal to the distribution device. In an alternative example, the biometric monitoring device 130 can be external to the distribution device. The biosensors can be coupled with any suitable item including, but are not limited to wearables, smart phones, clothing, implants, and remote biosensors. In at least one example, the biometric monitoring device 130 can be linked to the patient portal 112 via an account. The biometric monitoring device 130 can be operable to transmit the data back to the patient portal 112 on a real-time basis. The data collected by the biometric monitoring device 130 can then be stored in the patient database 114.
[0020] FIGS. 2A and 2B illustrate various cannabis distribution devices 140 which can be used in conjunction with the system 100 described with respect to FIG. 1. As described above, the distribution devices 140 described herein are any device suitable to allow for absorption of a cannabis derived compound 142 through the nasal passages and lungs. The distribution devices 140 as described herein can deliver the cannabis derived compound without requiring combustion of the compound. Specifically, FIG. 2A illustrates a distribution device 140 such as a face mask. The face mask can include surgical masks or procedure masks. Typically, such face masks are intended to be worn by health professionals during surgery and within medical facilities to catch any bacteria shed in the form of liquid droplets and aerosols from the wearer's mouth and nose. There are various ways to secure such masks to a wearer. The most popular is the ear-loop, where a string like material is attached to the mask and placed behind the ears. The others are the tie-on and the headband. The tie-on mask include four non-woven straps that are tied behind the head. The headband is an elastic strap that is placed behind or otherwise around the head. The face mask distribution device 140 can include a filter layer 144. In at least one example, the face mask can be multi-layered. For example, the face mask distribution device 140 can be three-ply, or consist of three filter layers 144. The filter layer 144 material can be a melt- blown material placed between non-woven fabrics. The melt-blown material can act as the filter that stops microbes from entering or exiting the face mask. Face mask can further feature pleats or folds. These pleats may be used to allow the user to expand the mask such that it covers the facial area from the nose to the chin.
[0021] The face mask distribution device 140 can also contain an aroma therapeutic layer 146 which can include at least one cannabis derived compound 142 and one or more additional compounds 148. The cannabis derived compounds 142 can be any cannabis compound as described in detail above. The additional compounds 148 can include any non-cannabis compounds, such as essential oils from other plants that may have additional or synergistic therapeutic effects. In at least some examples, the additional compounds 148 can be aromatic compounds including, but not limited to, an odorant, aroma, fragrance, flavor, and/or other chemical compound that is capable of producing a smell or odor. For example, the additional compounds 148 can include chemical compounds which cam produce a smell or odor due to being sufficiently volatile to be capable of transporting the additional compounds 148 to the olfactory system in the upper part of the nose. In at least one example, such molecules can have molecular weights of less than 300g/mol. Flavors may affect both the sense of taste and smell, whereas fragrances affect only smell. Some flavors tend to be naturally occurring, and some fragrances tend to be synthetic. In some examples, the additional compounds 148 can include, but are not limited to, esters, linear terpenes, cyclic terpenes, aromatics, amines, alcohols, aldehydes, ketones, lactones, theols, and/or other compounds.
[0022] An alternative exemplary distribution device 140 is illustrated in FIG. 2B. The distribution device 140 can be a distribution method coupled with an air source inducting, but not limited to, a non-forced air device, a forced air device, a positive airway pressure ventilator, a continuous positive airway pressure (CPAP) mask, a positive end-expiratory pressure (PEEP) ventilator, an oral mask, a naso-oral mask, a metered inhaler, a manually actuated inhaler, a breath-actuated inhaler, a mist inhaler, a nasal inhaler, a nasal pressure device, a maxillary advancement device (MAD), or any other device suitable to form an aerosol having the cannabis derived compound therein. For example, a distribution device 140 in accordance with FIG. 2B can include mask for use with CPAP treatments and an insert 170 can be an effective treatment for various afflictions induding moderate-to-severe obstructive sleep apnea. Typically, patients with obstructive sleep apnea can be treated with CF AP mask or nasal inhaler. During sleep, patients can a face mask which is connected to a pump, such as a CPAP machine, which forces air into the nasal passages at pressures high enough to overcome obstructions in the airway and stimulate normal breathing. The airway pressure delivered into the upper airway is continuous during both inspiration and expiration.
[0023] A distribution device 140 in accordance with FIG.2B can additionally include an insert 170 which allows cannabis derived compounds 142 to be secured in place in the distribution device 140 via a cannabis attachment 172. The cannabis attachment 172 can be any container suitable to contain a cannabis derived compound 142 and sized to fit within the insert 170 or the distribution device 140. The cannabis derived compound 142 can be distributed through the distribution device 140 at a predetermined rate which can be regulated by a regulator 180. Specifically, the cannabis attachment 172 allows the cannabis derived compounds 142 to enter the insert 170 of the distribution device 140 through the regulator 180 via an increase in air pressure. In some examples, the cannabis attachment 172 can contain cannabis derived compounds 142 which have been formulated with certain additives and excipients to provide a composition suitable for inhalation. In at least one example, the cannabis attachment 172 may be a reservoir containing an inhalable composition comprising at least one or more cannabinoids, a pharmaceutically acceptable medium, a propellant (such as butane, tetroxide, hydrocarbons, and fluorocarbons), a monohydric, dihydric, or polyhydric alcohol, and a glycol or glycol ether. The reservoir can be any container suitable to depressurize the formulation to allow for a pressurized release of the inhalable composition, The regulator 180 of the distribution device 140 can control the flow of the cannabis derived compounds 142 into the insert 170 based on a set of instructions provided by regulator software 182. For example, the regulator 180 may have a sensor such that the regulator software 182 is operable to test and determine if the cannabis attachment 172 is appropriately coupled with the insert 172. The regulator software 182 can be a software component that is operable to determine the instructions to provide to the regulator 180 based on the therapeutic needs of the patient using the distribution device 140. In at last one example, the regulator software 182 can communicate with the patient portal 112 described in FIG. 1 to receive information regarding the patient's affliction.
[0024] The function of the regulator software 182 is described with reference to FIG. 3. One skilled in the art will appreciate that, for this and other processes and methods disclosed herein, the functions performed in the processes and methods may be implemented in differing order. Furthermore, the outlined steps and operations are only provided as examples, and some of the steps and operations may be optional combined into fewer steps and operations, or expanded into additional steps and operations without detracting from the essence of the disclosed embodiments.
[0025] Specifically, a method 200 for using the regulator software 182 to dispense a cannabis-derived compound 142 can begin at block 210. At block 210, the regulator software 182 receives therapy instructions from one of the patient portal 112 or the matching system 122. The therapy instructions can include various elements such as a dosage or amount of cannabis derived compounds, a frequency at which the dosage should be repeated, and a duration for which the dosage should be taken. For example, set of therapy instructions can include cannabis derivative amount of 20% CBD and 5% CBD, a dosage frequency of 5 mg dose every 1 hour, and a duration of 8 hours. The foregoing therapy instructions is provided as exemplary only and is not intended to be limiting. It should be understood that any combination of various cannabis quantity, frequency of dosing, and duration may be provided. The set of therapy instructions can be determined, at least in part based on the desired duration of the therapeutic effect of the cannabis derived compound within the patient. For example, the therapeutic effect of the cannabis derived compound can have a delayed onset after the initiation of the treatment and can continue for a period of time after the final dosage of the therapy. As such, the set of therapy instructions, including the quantity, dosage, and duration can be adjusted to achieve the desired therapeutic effect. Once the therapy instructions are received, at block 220 the regulator software 182 can determine if a cannabis attachment 172 has been properly secured to the insert 170 of the distribution device 140. If the regulator software 182 determines that a cannabis attachment 172 has not been properly attached to the insert 170, the user can be alerted and tihe method 200 can circle back to block 210. The alert can include, but is not limited to, playing a tone, illuminating a light indicator, or displaying a message on the user device 110. In the alternative, if the cannabis attachment 172 is properly attached, the method 200 can proceed to block 230. At block 230, the user can start the therapy program. Once the therapy is initiated, the distribution device 140 can begin dispensing the cannabis derived compound 142 via the cannabis attachment 172 according to the therapy instructions received. For example, initiating the thereby can include initiating the regulator 180 to dispense 5mg of cannabis derived compound 142 from the cannabis attachment 172 every hour for a total of 8 horns. The regulator software 182 can ensure that the appropriate amount of cannabis derived compound 142 is ddivered to the user.
[0026] At block 240, the regulator software 182 can determine whether a biometric monitoring device 130 is being used by the user. For example, if a user does have a biometric monitoring device 130 the user can link the device to their patient portal 112. The regulator software 182 can communicate with the patient portal 112 via the communications network 160 as described with respect to FIG. 1. If a biometric monitoring device 130 is being used, the method 200 can proceed to block 250. At block 250, the biometric monitoring device 130 can monitor and record data relating to one or more biometric signs of the user. The biometric data can include, but is not limited to, heart rate, peripheral capillary oxygen saturation (SP02), blood pressure, temperature, breath rate, sleep state, and any other biological parameter which is capable of being monitored by a biometric sensor. The biometric data can be transmitted from the biometric monitoring device 130 to the patient portal 112 and stored in the patient database 114. The biometric monitoring device 130 can be monitor the biometric data of the user throughout the duration of the therapy treatment. The method 200 can then proceed to block 260 where the distribution device 140 continues to dispense the cannabinoid formulation including the cannabis derived compound 142 and the additional compounds 148. In at least one example, if the biometric monitoring device 130 determines that a biological parameter is outside a predetermined range it can alert the user (for example, through the patient portal 112). In at least one example, the biological parameter being outside a predetermined range can be indicative of the treatment therapy requiring an adjustment Additionally, the biometric monitoring device can be operable to end the therapy prior to the full treatment being received if the user's biological parameters are determined to be out of the predetermined range.
[0027] In tire alternative, if the user does not have a biometric monitoring device 130, the method 200 can proceed directly from block 230 to block 260 and continue dispensing the cannabinoid formulation.
[0028] After a period of time, the method 200 can proceed to block 270 and the regulator software 182 can determine whether or not the therapy has been completed. For example, the regulator software 182 can perform a test that may determine if the therapy duration (e.g., 8 hours) has passed. If the therapy has not been completed, the method 200 can circle back to block 260 and continue dispensing the cannabinoid formulation. If, in the alternative, the regulator software 180 determines at block 270 that the therapy has been completed the method 200 proceeds to block 280 and the program is ended.
[0029] The functioning of the patient portal 112 will now be explained with reference to FIG.
4. One skilled in the art will appreciate that, for this and other processes and methods disclosed herein, the functions performed in the processes and methods may be implemented in differing order. Furthermore, the outlined steps and operations are only provided as examples, and some of the steps and operations may be optional, combined into fewer steps and operations, or expanded into additional steps and operations without detracting from the essence of the disclosed embodiments.
[0030] Specifically, FIG.4 illustrates a method 300 for using the patient portal 112 to determine the therapy best suited for a user. The method 300 can begin at block 310 where a user logs into the patient portal 112 with an assigned user name and password. At block 320, the user may input patient parameters into a patient profile stored in the patient database 114. The patient parameters can include, but not limited to, the user's age, height weight sex and various other medical information. At block 330, the user may input information relating to the affliction which they wish to treat using the distribution device 140 into the patient profile. Afflictions can include, but are not limited to, acute or chronic conditions relating to ailments such as sleep related disorders (including, but not limited to, apnea, hypopnea, or continuous or sustained reduction in ventilation), anxiety, sore throat, nasal congestion, neuropathic pain, nausea, motion sickness, arthritis, neurodegenerative diseases or any other ailment that has been determined to be alleviated by the ingestion of cannabinoids. At block 340, the patient parameters and affliction information can be transferred from the patient database 114 to the matching system 122 to be processed by the matching algorithm 126.
[0031] Once the patient parameters are received at the matching system 122, the matching algorithm 126 can access the device database 124 to match an optimal distribution device 140 with the user's affliction. The device database 124 can include a complication of Various distribution devices 140 including, but not limited to, those discussed above. At block 350, the user can receive results from the matching algorithm 126 at the patient portal 112. The results can include a set of therapy instructions as described above (e.g., a CPAP mask with cannabinoid attachment, 20% CBD and 10% CBG, 5 mg, every hour for 8 hours while sleeping). Next, at block 360, the user can order a product based on the results of the matching algorithm 126. In at least one example, the user can order both a distribution device 140 and a cannabis derived compound 142, such as a CPAP mask and a cannabis attachment 172 having a formulation determined by the matching algorithm 126. In an alternative example, if the patient already has access to the matched distribution device 140, the patient can order only the cannabis derived compound 142. At block 370, the data can then be stored to the patient database 114. The data can include, but is not limited to, the patient parameters described above, affliction, matching algorithm results, and order history information. Finally, at block 380, the therapy instructions can be transmitted to the regulator software 182 as described above.
[0032] An exemplary patient database 114 is provided as Table 1 showing various data points that may be stored in the database including patient parameters, affliction, and matched therapy instructions.
Figure imgf000017_0001
Table 1
As illustrated, the patient database 114 can include information relating to various patients (Patient l, Patient 2, and Patient 3) including their age, height, and weight. The patient database can additionally include information relating to the patient's doctor, for example, the doctor information can include, but is not limited to, physician contact information. The patient database 114 can additionally include information relating to the patient's affliction and any previously matched therapies corresponding to the afflictions. In at least some examples the patient database 114 can further include information received from a biometric monitoring device. The biometric data can be used by the patient's doctor in order to update the matched therapy based on the patient's reaction to a previous therapy.
[0033] An exemplary device database 124 is provided as Table 2, below. As illustrated in the table, the device database 124 can include a compilation of various distribution devices compatible with the above described sy stems and methods including, but not limited to, surgical masks, CPAP masks, nasal inhalers, and the like. The device database 124 can additionally include the various afflictions that each distribution device can be used to treat. Treatment therapies relating to various distribution devices and afflictions can also be stored in the device database 124. including various cannabis derived compounds 142 including, but not limited to, cannabinoids, terpenes, and additional compounds, as well as recommended dosages for patients falling into predetermined parameters.
Figure imgf000018_0001
It should be understood that Table 2 is provided as an exemplary device database 124 and should not be considered as limiting. The device database 124 can include additional dements such as those described above.
[0034] The functioning of the matching algorithm 126 is explained with reference to FIG. 5. One skilled in the art will appreciate that, for this and other processes and methods disclosed herein, the functions performed in the processes and methods may be implemented in differing order. Furthermore, the outlined steps and operations are only provided as examples, and some of the steps and operations may be optional, combined into fewer steps and operations, or expanded into additional steps and operations without detracting from the essence of the disclosed embodiments.
[0035] Specifically, a method 400 for matching a distribution device 140 and a therapy to a patient is illustrated in FIG. 5. The method 400 can begin at block 41 where the matching algorithm 126 receives patient data including patient parameters and affliction from the patient portal 112. At block 420, tire patient parameters and affliction are matched with a treatment therapy in the stored in the device database. In at least one example, the matching algorithm 126 may require that the affliction must match exactly and that patient parameters must fall within a specified range of the proposed therapy. In an alternative example, the matching algorithm 126 can allow for a predetermined amount of variation between the affliction and patient parameters. [0036] At block 430, the matched therapy can then be transferred back to the patient portal
112. At block 440, the matched therapy can be stored in the patient database 114 along with the corresponding patient parameters and affliction. In at least one example, where the user has access to a biometric monitoring device the user can link the biometric device to their patient portal 112 such that the effect of the cannabis derived compound on the patient is recorded. In such cases, the method 400 can proceed to block 450, where the data obtained from the biometric monitoring device is received at the matching algorithm 126. As described above with respect to FIG. 2, the data from the biometric monitoring device 130 can be used to determine how the user responded to the therapy. The method 400 can then revert to bock 420 and the biometric data can be considered in updating the matched patient therapy. As such, the biometric data can assist in determining the best dosage and formulation for the riser based on their ailments.
[0037] The functioning of the ordering system 116 is explained with reference to FIG. 6. One skilled in the art will appreciate that, for this and other processes and methods disclosed herein, the functions performed in the processes and methods may be implemented in differing order. Furthermore, the outlined steps and operations are only provided as examples, and some of the steps and operations may be optional, combined into fewer steps and operations, or expanded into additional steps and operations without detracting from the essence of the disclosed embodiments.
[0038] Specifically, a method 500 for ordering a cannabis derived compound 142 is provided in FIG. 6. The method 500 can begin at block 510 where an order is received from the ordering system 116 of the patient portal 112. At block 520, the ordering system 116 retrieves the matched therapy from the patient database 114. At block 530, the method 500 determines whether or not approval is required from a medical professional in order to obtain the cannabis derived compound. For example, various jurisdictions require a prescription or medical approval to obtain a cannabis derived compounds. In such jurisdictions, the method 500 can proceed to block 540 where the ordering system 116 contacts the medical professional to approve the order. For example, the therapy instructions can be transmitted to and verified by the doctor listed in patient database 114. If the user's doctor approves, the method 500 can proceed to block 550 and the user's order payment is processed and therapy is shipped to patient
[0039] If the jurisdiction does not require medical professional approval, the method 500 can proceed directly from block 530 to block 550 and the order can be processed and the therapy shipped to the patient.
[0040] The foregoing detailed description of the technology has been presented for purposes of illustration and description. It is not intended to be exhaustive or to limit the technology to the precise form disclosed. Many modifications and variations are possible in light of the above teaching. The described embodiments were chosen in order to best explain the principles of the technology, its practical application, and to enable others skilled in the art to utilize the technology in various embodiments and with various modifications as are suited to the particular use contemplated. It is intended that the scope of the technology be defined by the claims.

Claims

CLAIMS WHAT IS CLAIMED IS:
1. A system for generating a cannabis-based therapy, the system comprising:
a patient database that stores a plurality of patient parameters and one or more afflictions associated with a patient;
a device database that stores a plurality of features relating to a plurality of distribution devices, each of the plurality of distribution devices operable to dispense a cannabis derived compound; and
a server that
receives the plurality of patient parameters and the one or more afflictions from the patient database,
executes a matching algorithm stored in a memory of the server, wherein the execution of the matching algorithm identifies a cannabis-based therapy based on the received patient parameters and afflictions, the identified canna-based therapy specifying one of the plurality of distribution devices and a formulation of the cannabis derived compound; and
transmits the cannabis-based therapy and a set of therapy instructions to a user device associated with the patient.
2. The system of claim 1, wherein the cannabis derived compound includes one or more of tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromene (CBC), cannabigerol (CBG), and combinations thereof.
3. The system of claim 2, wherein the formulation further includes one or more of a pharmaceutically acceptable medium, a propellant, an alcohol, and a glycol.
4. The system of claim 1, wherein the plurality of distribution devices include one or more of a face mask, a surgical mask, a non-forced air device, a forced air device, a positive airway pressure ventilator, a continuous positive airway pressure (CPAP) mask, a positive end- expiratory pressure (PEEP) ventilator, an oral mask, a naso-oral mask, a metered inhaler, a manually actuated inhaler, a breath-actuated inhaler, a mist inhaler, a nasal inhaler, a nasal pressure device, and a maxillary advancement device (MAD).
5. The system of claim 4, wherein the specified distribution device further includes an insert sized to accept a cannabis attachment, the cannabis attachment being a reservoir containing the formulation.
6. The system of claim 4, wherein the specified distribution device further includes an aroma therapeutic layer having the formulation disposed therein.
7. The system of claim 1, wherein the one or more afflictions include one or more of a sleep related disorder, anxiety, sore throat nasal congestion, neuropathic pain, nausea, motion sickness, arthritis, and neurodegenerative diseases.
8. The system of claim 1, wherein the plurality of patient parameters include one or more of an age, a weight, and a gender.
9. The system of claim 1, further comprising a biometric monitoring device operable to monitor one or more biological parameters of the patient including one or more of a heart rate, a peripheral capillary oxygen saturation (SP02), a blood pressure, a temperature, a breath rate, and a sleep state to obtain biometric data.
10. The system of claim 9, wherein the biometric monitoring device further receives biometric data relating to the one or more biological parameters from the patient portal over a communication network, and wherein the server further executes the matching algorithm on the received biometric data to generate an updated cannabis-based therapy.
11. The system of claim 1, wherein the set of therapy instructions includes at least a dosage, a frequency, and a duration.
12. A method for matching a cannabis-based therapy with a user, the method comprising: storing a plurality of patient parameters and one or more afflictions associated with a patient in a patient database;
transmitting, via a communications network, the plurality of patient parameters and one or more afflictions from the patient database to a server;
retrieving data from a device database regarding a plurality of features relating to a plurality of distribution devices operable to dispense a cannabis derived compound;
executing a matching algorithm stored in a memory of the server, wherein the execution of the matching algorithm identifies a cannabis-based therapy based on the received patient parameters and afflictions, the identified canna-based therapy specifying one of the plurality of distribution devices and a formulation of the cannabis derived compound; and
transmitting the cannabis-based therapy and a set of therapy instructions to a user device associated with the patient .
13. The method of claim 12, wherein the cannabis derived compound includes one or more of tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromene (CBC), cannabigerol (CBG), and combinations thereof.
14. The method of claim 13, wherein the formulation further includes one or more of a pharmaceutically acceptable medium, a propellant, an alcohol, and a glycol.
15. The method of claim 12, wherein the plurality of distribution devices include one or more of a face mask, a surgical mask, a non-forced air device, a forced air device, a positive airway pressure ventilator, a continuous positive airway pressure (CPAP) mask, a positive end- expiratory pressure (PEEP) ventilator, an oral mask, a naso-oral mask, a metered inhaler, a manually actuated inhaler, a breath-actuated inhaler, a mist inhaler, a nasal inhaler, a nasal pressure device, and a maxillary advancement device (MAD).
16. The method of claim 12, wherein the one or more afflictions include one or more of a sleep related disorder, anxiety, sore throat nasal congestion, neuropathic pain, nausea, motion sickness, arthritis, and neurodegenerative diseases.
17. The method of claim 12, wherein the patient parameters include one or more of an age, a weight, and a gender.
18. The method of claim 12, further comprising:
receiving biometric data obtained via a biometric monitoring device, the biometric data corresponding to one or more biological parameters of the patient; and
executing the matching algorithm on the received biometric data to generate an updated cannabis-based therapy.
19. The method of claim 12, wherein the set of therapy instructions includes at least a dosage, a frequency, and a duration.
20. A huh-transitory, computer-readable storage medium, having embodied thereon a program executable by a processor to perform a method for generating a cannabis-based therapy, the method comprising:
storing a plurality of patient parameters and one or more afflictions associated with a patient in a patient database;
transmitting, via a communications network, the plurality of patient parameters and one or more afflictions from the patient database to a server
retrieving data from a device database regarding a plurality of features relating to a plurality of distribution devices operable to dispense a cannabis derived compound;
executing a matching algorithm stored in a memory of the server, wherein the execution of the matching algorithm identifies a cannabis-based therapy based on the received patient parameters and afflictions, the identified canna-based therapy specifying one of the plurality of distribution devices and a formulation of the cannabis derived compound; and
transmitting the cannabis-based therapy and a set of therapy instructions to a user device associated with the patient
PCT/IB2020/050998 2019-02-11 2020-02-08 Nasal inhaler with combined treatments WO2020165715A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US201962804073P true 2019-02-11 2019-02-11
US62/804,073 2019-02-11

Publications (1)

Publication Number Publication Date
WO2020165715A1 true WO2020165715A1 (en) 2020-08-20

Family

ID=72044706

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2020/050998 WO2020165715A1 (en) 2019-02-11 2020-02-08 Nasal inhaler with combined treatments

Country Status (1)

Country Link
WO (1) WO2020165715A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000041662A1 (en) * 1999-01-13 2000-07-20 Goldshtein Yakov A Face mask or bandage
US20160171164A1 (en) * 2014-12-16 2016-06-16 Craig E. Kinzer Connected systems, devices, and methods including cannabis profile management
US20160335543A1 (en) * 2015-05-13 2016-11-17 Potbotics, Inc. Method and system for medical cannabinoid treatment and product selection
US20170157343A1 (en) * 2014-06-30 2017-06-08 Syqe Medical Ltd. Methods, devices and systems for pulmonary delivery of active agents
WO2019084525A1 (en) * 2017-10-27 2019-05-02 Hey Mary, Llc. Systems, methods, and apparatus for tailored dosing of cannabis formulations

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000041662A1 (en) * 1999-01-13 2000-07-20 Goldshtein Yakov A Face mask or bandage
US20170157343A1 (en) * 2014-06-30 2017-06-08 Syqe Medical Ltd. Methods, devices and systems for pulmonary delivery of active agents
US20160171164A1 (en) * 2014-12-16 2016-06-16 Craig E. Kinzer Connected systems, devices, and methods including cannabis profile management
US20160335543A1 (en) * 2015-05-13 2016-11-17 Potbotics, Inc. Method and system for medical cannabinoid treatment and product selection
WO2019084525A1 (en) * 2017-10-27 2019-05-02 Hey Mary, Llc. Systems, methods, and apparatus for tailored dosing of cannabis formulations

Similar Documents

Publication Publication Date Title
EP3399972B1 (en) Low dose therapeutic treatment
Pollack Jr et al. Treatment of acute bronchospasm with β-adrenergic agonist aerosols delivered by a nasal bilevel positive airway pressure circuit
CN100381184C (en) Apparatuses and methods for providing a conscious patient relief from pain and anxiety associated with medical or surgical procedures according to appropriate clinical heuristics
US20160211693A1 (en) Systems and methods for a vaporization device and product usage control and documentation
CN1622839B (en) Patient monitoring system and nursing system
US7185650B2 (en) Systems and methods for determining a minimum effective dose of an inhaled drug for an individual patient at a given time
Bisgaard et al. Drug delivery to the lung
KR20070109974A (en) Methods and kits for delivering drugs by nebulisation
Saeed et al. Modeling and optimization of nebulizers' performance in non-invasive ventilation using different fill volumes: comparative study between vibrating mesh and jet nebulizers
AU2020202487B2 (en) Methods of administering high concentrations of nitric oxide
MX2013008688A (en) Patient-controlled aerosol administration.
EP2825179A1 (en) Methods of administering high concentrations of nitric oxide
WO2020165715A1 (en) Nasal inhaler with combined treatments
US20190275270A1 (en) System and method for arresting debilitating migraine events
Boyd The continued need for metered dose inhalers
Runo et al. Evidence-Based Case Review: Treating dyspnea in a patient with advanced chronic obstructive pulmonary disease
Lamont et al. Re: COVID-19–Administering medications via inhalations–Long-term care
US20220040421A1 (en) A multi-users medical cannabis dispenser
Shrestha et al. Comparison of bronchodilator effect of salbutamol delivered via MDI and DPI in COPD patients
Romito Perioperative Management of the Tobacco User
Madney et al. The impact of changing patient interfaces on delivering aerosol with titrated oxygen in the high flow system
Almukhambetova et al. Nebulising therapy of bronchial asthma attacks
Hauptman The virtual COPD visit in the COVID-19 pandemic
Hanlon Aerosol delivery: efficiency and effectiveness vary: several types of aerosol delivery technology exist on the market today, but depending on the specific disease being treated, certain devices may make more sense for patients
Zar Alternate spacer devices in the treatment of asthma in children

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20755379

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20755379

Country of ref document: EP

Kind code of ref document: A1